Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs JANX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

JANX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 3–4 Matrix Metrics)

JANX Overall Winner 6-Pillar Tally: NTLA 3 – 3 JANX Matrix Metrics: NTLA 4 – 3 JANX

As of Nov 16, 2026, Janux Therapeutics, Inc. (JANX) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). NTLA carries a Unified Composite Score of 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas JANX carries 45.0/100 (HOLD) at $10.89 (N/M Forward P/E, -599.3% operating margin).

  • Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. JANX 45.0/100 HOLD), JANX captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-599.3% vs. -826.0% operating margin) and revenue trajectory (-7.1% vs. -48.0% YoY).
  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile JANX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs JANX
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $11.58 · SMA50: $11.86
JANX NASDAQ Head-to-Head Winner
Janux Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$10.89
-4.22% 1D
Market Cap $703.3M
TTM Revenue $23M
Forward P/E N/M
Beta / 30D Vol 0.74β · 118% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 35.0 Fund 51.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.0%), weak momentum, RSI 28
RSI-14: 27.7 · SMA20: $15.66 · SMA50: $16.61

6-Pillar Scorecard Institutional Category Breakdown (NTLA 3 – 3 JANX)

Columns: Metric · NTLA · JANX
1. Valuation Multiples NTLA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 29.1x 29.3x
2. Growth & Scale NTLA
Revenue Growth (YoY) -48.0% -7.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $23M
Market Cap $1.5B $703.3M
3. Profitability & Quality JANX
Gross Margin N/A N/A
Operating Margin -826.0% -599.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.6% -10.6%
4. Balance Sheet & Cash Flow JANX
Cash Generation (TTM) -$358M -$54M
Cash Flow Margin N/A N/A
Net Cash / Leverage $74M Net Debt (0.38x D/E) $21M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning JANX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 101.3% (78th %ile) 57.7% (11th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 148.09x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (4) vs JANX (3)
Institutional Metric NTLA JANX Criterion Row Edge
Market Capitalization
Scale
$1.5B $703.3M Larger Scale NTLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-48.0% -7.1% Higher Growth JANX
Operating Margin (TTM)
Profitability
-826.0% -599.3% Higher Margin JANX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.6% -10.6% Higher ROE JANX
52-Week Range Position
Momentum
20% ($8–$18) 1% ($11–$35) Stronger Trend NTLA
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 0.74β · 118% Vol Lower Realized Risk NTLA
Unified Institutional Score
Composite Signal
50.7 / 100 (HOLD) 45.0 / 100 (HOLD) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$53M $23M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 29.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$54M ($21M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NTLA +21.61 pp
NTLA: -12.43% · JANX: -34.04%
3M Horizon NTLA +22.0 pp
NTLA: -13.79% · JANX: -35.79%
6M Horizon NTLA +1.18 pp
NTLA: -21.2% · JANX: -22.38%
1Y Horizon NTLA +75.68 pp
NTLA: +15.34% · JANX: -60.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue JANX Revenue NTLA Op. Margin JANX Op. Margin Margin Leader
FY2018 $30M N/A -298.6% N/A NTLA
FY2019 $40M N/A -246.8% N/A NTLA
FY2020 $60M N/A -235.5% N/A NTLA
FY2021 $30M $0M -810.4% -905.4% NTLA
FY2022 $50M $10M -879.0% -779.0% JANX
FY2023 $40M $10M -1420.5% -902.9% JANX
FY2024 $60M $10M -923.1% -933.6% NTLA
FY2025 $70M $10M -651.7% -1576.7% NTLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
JANX BREAKDOWN
51d in phase · OBV DISTRIBUTION
Current IV 57.7%
IV Percentile 11th %ile
Put/Call OI Skew 148.09x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact JANX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
JANX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $703.3M market capitalization and -599.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs JANX Key Questions & Quantitative Answers

As of Nov 16, 2026, Janux Therapeutics, Inc. (JANX) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). NTLA carries a Unified Composite Score of 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas JANX carries 45.0/100 (HOLD) at $10.89 (N/M Forward P/E, -599.3% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. JANX 45.0/100 HOLD), JANX captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-599.3% vs. -826.0% operating margin) and revenue trajectory (-7.1% vs. -48.0% YoY). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile JANX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NTLA leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with JANX at -7.1% YoY revenue growth and +0.0% YoY earnings growth on $23M TTM revenue (N/A gross margin, -599.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while JANX shifted +0.0%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for JANX.

NTLA screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas JANX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus JANX (-10.6% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, JANX carries 57.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 148.09x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.74β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.